16:07 08/03/2017 Maxim Shares Two Cents on AEterna Zentaris Inc. (USA) (AEZS) Following ...
Maxim Shares Two Cents on AEterna Zentaris Inc. (USA) (AEZS) Following ...
Smarter Analyst - Mar 8, 2017
Maxim analyst Jason Kolbert is optimistic on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on the heels of the biotech firm indicating that the Pediatric Committee of EMA will allow AEZS to file a Marketing Authorization Application (MAA) before overseeing ...
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has been downgraded to Hold in a ... - Breaking Finance News

14:00 07/03/2017 Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces EMA ...
Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces EMA ...
Smarter Analyst - Mar 7, 2017
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Pediatric Committee (“PDCO”) of the European Medicines Agency (“EMA”) agreed to the Company's Pediatric Investigation Plan (“PIP”) for Macrilen™ and agreed that the Company may defer ...

18:25 14/02/2017 AEterna Zentaris Inc. (USA) (AEZS): Macrilen gets an “A” – Maxim
AEterna Zentaris Inc. (USA) (AEZS): Macrilen gets an “A” – Maxim
Smarter Analyst - Feb 14, 2017
Maxim analyst Jason Kolbert weighed in on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) with a $10.00 price target, after the company announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial ...

12:56 13/02/2017 Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces Plans to ...
Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces Plans to ...
Smarter Analyst - Feb 13, 2017
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD ...

18:41 31/01/2017 Maxim Weighs In On AEterna Zentaris Inc. (USA) (AEZS) As Zoptrex Completes ...
Maxim Weighs In On AEterna Zentaris Inc. (USA) (AEZS) As Zoptrex Completes ...
Smarter Analyst - Jan 31, 2017
Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) jumped over 20% today, after the drug maker announced the completion of the clinical phase of its pivotal Phase 3 clinical study of Zoptrex in endometrial cancer (EC), which was conducted under a ...

15:59 17/01/2017 Maxim Boosts Price Target for AEterna Zentaris Inc. (USA) (AEZS); Shares Rose 11%
Maxim Boosts Price Target for AEterna Zentaris Inc. (USA) (AEZS); Shares Rose 11%
Smarter Analyst - Jan 17, 2017
Maxim analyst Jason Kolbert is out with a bullish research report today on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) just one week after the biotech firm announced its Phase 3 clinical trial of Macrilen failed to achieve the primary objective.
Despite Failed Clinical Trial, Upside Potential Remains for Aeterna Zentaris ... - Economic Calendar

12:06 05/01/2017 AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Is Down, But Probably Not Out
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Is Down, But Probably Not Out
Market Exclusive - Jan 5, 2017
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) is taking a major hit premarket, having put out data from its lead trial after hours on Wednesday.
Poor Phase III trial outcome knocks third off Aeterna Zentaris share price - The Pharma Letter (registration)

19:58 16/11/2016 HC Wainwright Weighs in on AEterna Zentaris Inc. (USA) (AEZS) Post Q3 Update
HC Wainwright Weighs in on AEterna Zentaris Inc. (USA) (AEZS) Post Q3 Update
Smarter Analyst - Nov 16, 2016
On November 9th, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) posted third-quarter financial earnings and held a conference call.

13:27 26/10/2016 Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Completes Patient ...
Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Completes Patient ...
Smarter Analyst - Oct 26, 2016
AEZS AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has successfully completed patient recruitment for the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) as a growth hormone stimulation test for the evaluation of growth hormone ...

18:55 11/07/2016 HC Wainwright Analyst Pounds the Table on AEterna Zentaris Inc. (USA)
HC Wainwright Analyst Pounds the Table on AEterna Zentaris Inc. (USA)
Smarter Analyst - Jul 11, 2016
H.C. Wainwright analyst Swayampakula Ramakanth was out pounding the table on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Monday, reiterating a Buy rating and price target of $12, which represents a potential upside of 258% from where the stock is ...